<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> or the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> have an elevated risk of developing <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Until recently, strategies to reduce cardiovascular risk in these patients focused mainly on controlling glycemia and blood pressure as a means of preventing disease progression </plain></SENT>
<SENT sid="2" pm="."><plain>However, the <z:mp ids='MP_0005266'>metabolic abnormalities</z:mp> that cluster both in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> are <z:hpo ids='HP_0000001'>all</z:hpo> independent risk factors for atherogenesis </plain></SENT>
<SENT sid="3" pm="."><plain>There is now substantial evidence that <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> is an important, modifiable risk factor for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> or the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Recent sub-group analyses of landmark <z:chebi fb="0" ids="35664">statin</z:chebi> trials, such as the Heart Protection Study (<z:chebi fb="0" ids="32413">HPS</z:chebi>), confirm that the benefits of intensive <z:chebi fb="0" ids="35664">statin</z:chebi> therapy on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk extend to patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, irrespective of baseline <z:chebi fb="23" ids="18059">lipid</z:chebi> levels </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, the Collaborative AtoRvastatin <z:mp ids='MP_0002055'>Diabetes</z:mp> Study (CARDS), the first <z:chebi fb="0" ids="35664">statin</z:chebi> study to focus solely on patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, was stopped early due to the overwhelming benefits of <z:chebi fb="0" ids="35664">statin</z:chebi> therapy on cardiovascular risk in a study population who previously would not have been considered dyslipidemic (mean baseline <z:chebi fb="1" ids="47774">low-density lipoprotein cholesterol</z:chebi> [<z:chebi fb="0" ids="47774">LDL-C</z:chebi>], 3.0 mmol/l [116 mg/dl]) </plain></SENT>
<SENT sid="6" pm="."><plain>As a result, treatment guidelines are setting increasingly stringent goals for <z:chebi fb="0" ids="47774">LDL-C</z:chebi> levels in an attempt to reduce cardiovascular risk </plain></SENT>
<SENT sid="7" pm="."><plain>However, with physicians estimating that approximately 50% of patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> do not achieve these goals, initiation of appropriate, effective and rapid-acting <z:chebi fb="0" ids="35664">statin</z:chebi> therapy is paramount in these high-risk patients </plain></SENT>
</text></document>